Ahmed Almomani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmed Almomani has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Hakeem
National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
7 shared publications - Barry F. Uretsky
Central Arkansas Veterans Health System, Little Rock, Arkansas, USA; University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
5 shared publications Jason Payne
5 shared publications- Naga Venkata Pothineni
Kansas City Heart Rhythm Institute, Overland Park, USA
5 shared publications - Masood Ahmad
Division of Cardiovascular Medicine University of Texas Medical Branch Galveston Texas USA
4 shared publications Srikanth Kasula
4 shared publications
Latest Publications
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e047683
Contemporary Trends in High‐Potency P2Y12 Receptor Inhibitor Use Among Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Background: High‐potency P2Y12 receptor inhibitors (ticagrelor and prasugrel) reduce ischemic outcomes compared with clopidogrel among patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). This study aims to examine contemporary trends and identify predictors of their use among patients with AMI undergoing PCI in the United States. Methods: This observational study used electronic health records from >95 US‐based health care organizations. Adults with AMI who underwent PCI between 2016 and 2023 were included. The primary outcome was the prescription of high‐potency P2Y12 receptor inhibitors versus clopidogrel. Multivariable logistic regression was used to identify independent predictors of P2Y12 inhibitor selection. Results: Among 182 986 patients with AMI who underwent PCI , clopidogrel was the most prescribed P2Y12 receptor inhibitor (101 136 patients, 55.2%), followed by ticagrelor (68 350, 37.4%) and prasugrel (13 500, 7.4%). Clopidogrel use declined from 66.2% in 2016 to 51.4% in 2023 ( P trend =0.002), whereas ticagrelor use increased from 27.8% to 39.4% ( P trend =0.022), and prasugrel use increased from 6.0% to 9.2% ( P trend =0.008), predominantly after 2019. High‐potency P2Y12 receptor inhibitors were more frequently used in younger patients (<60 years), those with prior PCI , prior MI , chronic kidney disease, and morbid obesity. Conclusions: Among patients with AMI undergoing PCI, the use of high‐potency agents continues to rise. Prasugrel use increased notably after 2019, following the ISAR‐REACT 5 (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome) trial and the European guideline updates. These findings reflect an evolving prescribing landscape of P2Y12 receptor inhibitors in contemporary practice.
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e047683
Contemporary Trends in High‐Potency P2Y12 Receptor Inhibitor Use Among Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Background: High‐potency P2Y12 receptor inhibitors (ticagrelor and prasugrel) reduce ischemic outcomes compared with clopidogrel among patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). This study aims to examine contemporary trends and identify predictors of their use among patients with AMI undergoing PCI in the United States. Methods: This observational study used electronic health records from >95 US‐based health care organizations. Adults with AMI who underwent PCI between 2016 and 2023 were included. The primary outcome was the prescription of high‐potency P2Y12 receptor inhibitors versus clopidogrel. Multivariable logistic regression was used to identify independent predictors of P2Y12 inhibitor selection. Results: Among 182 986 patients with AMI who underwent PCI , clopidogrel was the most prescribed P2Y12 receptor inhibitor (101 136 patients, 55.2%), followed by ticagrelor (68 350, 37.4%) and prasugrel (13 500, 7.4%). Clopidogrel use declined from 66.2% in 2016 to 51.4% in 2023 ( P trend =0.002), whereas ticagrelor use increased from 27.8% to 39.4% ( P trend =0.022), and prasugrel use increased from 6.0% to 9.2% ( P trend =0.008), predominantly after 2019. High‐potency P2Y12 receptor inhibitors were more frequently used in younger patients (<60 years), those with prior PCI , prior MI , chronic kidney disease, and morbid obesity. Conclusions: Among patients with AMI undergoing PCI, the use of high‐potency agents continues to rise. Prasugrel use increased notably after 2019, following the ISAR‐REACT 5 (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome) trial and the European guideline updates. These findings reflect an evolving prescribing landscape of P2Y12 receptor inhibitors in contemporary practice.
- Open Access
- 1 February 2017
- Published by Wiley in Clinical Case Reports
- Vol. 5 (3) , 270-276
Chronic lead malposition diagnosis and management: discussion of two cases and literature review
Key Clinical Message: Management of lead malposition is crucial to avoid complications and is carried out on case‐by‐case bases. The 12‐lead ECG during pacing and chest X‐ray are essential during initial workup and recommended for new patients to the device clinic. Echocardiography and CT scan are important to confirm the location and plan appropriate therapy.
- 1 February 2017
- Published by Wiley in Clinical Case Reports
- Vol. 5 (3) , 270-276
Open AccessChronic lead malposition diagnosis and management: discussion of two cases and literature review
Key Clinical Message: Management of lead malposition is crucial to avoid complications and is carried out on case‐by‐case bases. The 12‐lead ECG during pacing and chest X‐ray are essential during initial workup and recommended for new patients to the device clinic. Echocardiography and CT scan are important to confirm the location and plan appropriate therapy.
- 1 February 2017
- Published by Elsevier in American Heart Journal
- Vol. 184, 10-16
Clinical and angiographic predictors of persistently ischemic fractional flow reserve after percutaneous revascularization
- 1 February 2017
- Published by Elsevier in American Heart Journal
- Vol. 184, 10-16
Clinical and angiographic predictors of persistently ischemic fractional flow reserve after percutaneous revascularization
- 1 November 2016
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 2 (6) , 682-690
Incidence of Atrial Fibrillation After Atrial Flutter Ablation
- 1 November 2016
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 2 (6) , 682-690
Incidence of Atrial Fibrillation After Atrial Flutter Ablation